Guo Qiaoyan, Chen Yangyang, Yang Liming, Zhu Xueyan, Zhang Xiaoxuan, Zhao Qiao, Zhuang Xiaohua, Wu Yanfeng, Luo Ping, Cui Wenpeng
Department of Nephrology, The Second Hospital of Jilin University, Changchun, China.
Department of Nephrology, Second Part of the First Hospital of Jilin University, Changchun, China.
Blood Purif. 2022;51(3):280-287. doi: 10.1159/000514938. Epub 2021 Oct 12.
The impact of early-onset peritonitis (EOP) on patients with diabetes undergoing peritoneal dialysis (PD) has not been adequately addressed. We therefore sought to investigate the effects of EOP on the therapeutic response to management and long-term prognostic outcomes in patients with diabetes undergoing PD.
For this retrospective cohort study, we analyzed the data for patients with end-stage renal disease, who were also suffering from diabetes mellitus and had undergone PD between January 1, 2013, and December 31, 2018. EOP was defined as the first episode of peritoneal dialysis-related peritonitis (PDAP) occurring within 12 months of PD initiation. All patients were divided into an EOP group and a later-onset peritonitis (LOP) group. Clinical data, treatment results, and outcomes were compared between groups.
Ultimately, 202 patients were enrolled for the analysis. Compared to the EOP group, the LOP group had more Streptococcus (p = 0.033) and Pseudomonas (p = 0.048). Patients with diabetes in the EOP group were less likely to have PDAP-related death (OR 0.13, CI: 0.02-0.82, p = 0.030). Patients with diabetes in the EOP group were more likely to have multiple episodes of PDAP and had higher rates of technical failure and poorer patient survival than those in the LOP group, as indicated by Kaplan-Meier analysis (p = 0.019, p = 0.004, and p < 0.001). In the multivariate Cox proportional hazards model, EOP was a significant predictor for multiple PDAP (HR 4.20, CI: 1.48-11.96, p = 0.007), technical failure (HR 6.37, CI: 2.21-18.38, p = 0.001), and poorer patient survival (HR 3.09, CI: 1.45-6.58, p = 0.003).
The occurrence of EOP is significantly associated with lower rates of PDAP-related death and poorer clinical outcomes in patients with diabetes undergoing PD.
早发性腹膜炎(EOP)对接受腹膜透析(PD)的糖尿病患者的影响尚未得到充分研究。因此,我们试图探讨EOP对接受PD的糖尿病患者治疗反应及长期预后的影响。
在这项回顾性队列研究中,我们分析了2013年1月1日至2018年12月31日期间患有终末期肾病且同时患有糖尿病并接受PD治疗的患者的数据。EOP定义为在开始PD治疗后12个月内发生的首次腹膜透析相关腹膜炎(PDAP)。所有患者分为EOP组和迟发性腹膜炎(LOP)组。比较两组的临床数据、治疗结果和预后。
最终,202例患者纳入分析。与EOP组相比,LOP组链球菌(p = 0.033)和假单胞菌(p = 0.048)感染更多。EOP组的糖尿病患者发生PDAP相关死亡的可能性较小(OR 0.13,CI:0.02 - 0.82,p = 0.030)。Kaplan - Meier分析表明,EOP组的糖尿病患者发生PDAP的次数更多,技术失败率更高,患者生存率低于LOP组(p = 0.019,p = 0.004,p < 0.001)。在多变量Cox比例风险模型中,EOP是多次发生PDAP(HR 4.20,CI:1.48 - 11.96,p = 0.007)、技术失败(HR 6.37,CI:2.21 - 18.38,p = 0.001)和患者生存率较差(HR 3.09,CI:1.45 - 6.58,p = 0.003)的显著预测因素。
EOP的发生与接受PD治疗的糖尿病患者中较低的PDAP相关死亡率及较差的临床结局显著相关。